BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene & Cell Therapy

Vaccitech plc (NASDAQ: VACC), today announced that Tom Evans, M.D., Vaccitech’s Chief Scientific Officer will present an update on the Company’s chronic hepatitis B (CHB) immunotherapeutic Phase 1b/2a trial at The World Vaccine Congress Europe on October 21 in Barcelona, Spain.

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader (KOL) webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease.

Prime Medicine™, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, announced the appointment of Ann L. Lee, PhD, as Chief Technical Officer.

Poseida Therapeutics, Inc. today announced appointments to new roles on its executive leadership team.

Mereo BioPharma Group plc, “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, the Osteogenesis Imperfecta Federation Europe and the Osteogenesis Imperfecta Foundation announced completion of enrollment in the largest global gathering of data to date about the impact that OI has on people with OI, their families and caregivers.

NeuroBo Pharmaceuticals, Inc. today announced that an independent Data Monitoring Committee (DMC) reviewed safety data from 36 patients treated in the Phase 2/3 clinical trial of NeuroBo’s lead drug candidate, ANA001, a proprietary oral niclosamide formulation being developed as a potential treatment for COVID-19.

NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced the pricing of an underwritten registered public offering of 3,750,000 shares of its common stock at a price of $3.20 per share.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And System For Monitoring Tissue Temperature” from the United States Patent & Trademark Office.

Incyte announced that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 2, 2021.